#392Extended selection 101–500

Xeris Biopharma

Midwest / Texas

BiologicsPeptides and metabolic medicines

Manufacturing profile

Biologics
Peptides and metabolic medicines

Biopharma hub: Midwest / Texas

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Cell bank or microbial seed
  2. 2Upstream culture or fermentation
  3. 3Clarification and chromatography
  4. 4UF/DF, formulation and sterile filtration
  5. 5SEC, CE, LC-MS, ELISA, qPCR and bioassay QC
  6. 6Peptide synthesis or recombinant upstream
  7. 7Chromatography and UF/DF
  8. 8HPLC/LC-MS and CE peptide mapping
  9. 9Sterile filtration and cartridge/vial filling

Relevant FUZKK packages

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology